Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer revision number advances from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:07:46.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study details, replacing the content with a basic header/footer and preventing access to the study record.
    Difference
    18%
    Check dated 2026-09-22T23:52:19.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The revision tag on the page was updated from v3.6.6 to v3.7.0, indicating a newer version of the Study Details page rendering. This is an internal version update rather than a change to visible study information.
    Difference
    0.1%
    Check dated 2026-09-16T00:10:15.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The MedlinePlus related topics entry for Melanoma, the MedlinePlus Genetics link, and the related topics header have been removed. This reduces external resource references on the study page without changing the core study details.
    Difference
    0.2%
    Check dated 2026-09-08T22:38:04.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The related topics section now lists Melanoma and MedlinePlus Genetics. The page revision tag has been updated from v3.6.5 to v3.6.6.
    Difference
    0.2%
    Check dated 2026-09-01T19:21:33.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The page loses the 'Melanoma' condition tag, the 'related topics:' section header, and the MedlinePlus Genetics link, altering how the study's disease focus and related resources are presented on the page.
    Difference
    0.2%
    Check dated 2026-08-25T16:35:21.000Z thumbnail image

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.